By Fineline Cube 
Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, announced it has received marketing approval from China’s National Medical Products Administration (NMPA) for Juvéderm VOLUMA with Lidocaine with a specific indication for the temple area. The cross-linked sodium hyaluronate gel for injection is now approved for supraperiosteal injection in the temporal region to improve temple hollowing, marking it as the first hyaluronic acid filler approved in China for this aesthetic indication.
Regulatory Approval Details
| Parameter | Detail |
|---|---|
| Product | Juvéderm VOLUMA with Lidocaine |
| Indication | Supraperiosteal injection in temporal region for temple hollowing improvement |
| Regulatory Agency | National Medical Products Administration (NMPA), China |
| Approval Significance | First hyaluronic acid filler approved in China for temple indication |
| Company | Allergan Aesthetics (AbbVie subsidiary) |
Pivotal Phase III Clinical Data
The NMPA approval was supported by results from a multi-center, randomized, blank-controlled, evaluator-blinded Phase III study conducted specifically in the Chinese population:
| Endpoint | Result |
|---|---|
| Primary Endpoint | ATHS (Aesthetic Temple Hollowing Scale) response rate |
| ATHS Response Rate | 90.5% at six months post-treatment |
| Investigator GAIS Improvement | >92% |
| Subject GAIS Improvement | >92% |
| Safety Profile | Favorable safety and tolerability demonstrated |
The Global Aesthetic Improvement Scale (GAIS) scores exceeding 92% for both investigators and subjects indicate high levels of satisfaction with treatment outcomes from both clinical and patient perspectives.
Market Impact & Strategic Context
- China Aesthetics Market: Rapidly growing segment valued at over $15 billion annually, with increasing demand for non-surgical facial rejuvenation procedures
- Temple Aesthetics Gap: Temple hollowing represents a common aging concern in Asian populations, previously lacking approved hyaluronic acid solutions
- Competitive Advantage: First-mover status provides significant market positioning benefits in a category with high barriers to entry due to regulatory requirements
- Portfolio Expansion: Strengthens Allergan Aesthetics’ Juvéderm franchise in China, complementing existing facial contouring and wrinkle treatment indications
- Revenue Potential: Temple treatments typically command premium pricing, with estimated procedure costs 20-30% higher than standard facial filler applications
This approval reinforces AbbVie’s commitment to expanding its aesthetics portfolio in key international markets and addresses a significant unmet need in the Chinese aesthetic medicine landscape.
Forward‑Looking Statements
This brief contains forward-looking statements regarding market opportunities, regulatory approvals, and commercial expectations. Actual results may differ due to risks including market adoption rates, competitive dynamics, and evolving regulatory requirements in the aesthetics sector.-Fineline Info & Tech